PetCure Oncology™ is currently recruiting patients for a clinical trial evaluating the effectiveness of stereotactic radiosurgery (SRS) for the treatment of post-surgical, grade 2 soft tissue sarcoma in dogs using a liquid fiducial marker.
Historically, stereotactic radiation (SRS/SRT) has not been an available treatment option for pet patients who have undergone surgery to remove a malignant tumor. This is due to the lack of an appropriate treatment target, among other factors.
A liquid fiducial marker can be injected along a surgical incision or painted into a resection cavity for later imaging. This allows for the creation of an artificial target that can then be treated with SRS in a single fraction, rather than the 19-21 fractions typically recommended for the treatment of an incompletely resected soft tissue sarcoma. Prior to the launch of this study, PetCure Oncology conducted a pilot study of 20 canine patients whose treatment plans were created using the PetXMark liquid fiducial marker. The pilot study did not result in any acute toxicity, local failures, or geographic misses.
If your dog has soft tissue sarcoma that has residual cancer following surgery, or if you are a veterinarian with a canine patient meeting this criteria, they may be eligible for single-fraction SRS treatment through this clinical trial.
PET OWNERS VETERINARIANS